GILD 3 Biotech Stocks to Watch as FDA Approvals Roll In - StockNews.com
| 4132 Stock | TWD 16.55 0.45 2.65% |
Slightly above 62% of Golden Biotechnology's investor base is looking to short. The analysis of current outlook of investing in Golden Biotechnology suggests that many traders are alarmed regarding Golden Biotechnology's prospects. Golden Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Golden Biotechnology's earnings reports, geopolitical events, and overall market trends.
Golden Biotechnology stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Golden daily returns and investor perception about the current price of Golden Biotechnology as well as its diversification or hedging effects on your existing portfolios.
Golden |
GILD 3 Biotech Stocks to Watch as FDA Approvals Roll In StockNews.com
Read at news.google.com
 |
Golden Biotechnology Fundamental Analysis
We analyze Golden Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Golden Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Golden Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Golden Biotechnology is number one stock in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Golden Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Golden Biotechnology stock to make a market-neutral strategy. Peer analysis of Golden Biotechnology could also be used in its relative valuation, which is a method of valuing Golden Biotechnology by comparing valuation metrics with similar companies.
Peers
Golden Biotechnology Related Equities
| 1720 | Standard Chemical | 1.26 | ||||
| 1707 | Grape King | 0.65 | ||||
| 3705 | YungShin Global | 0.34 | ||||
| 4119 | SCI Pharmtech | 0.51 | ||||
| 1789 | ScinoPharm Taiwan | 0.63 | ||||
| 4132 | Golden Biotechnology | 2.65 |
Additional Tools for Golden Stock Analysis
When running Golden Biotechnology's price analysis, check to measure Golden Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Golden Biotechnology is operating at the current time. Most of Golden Biotechnology's value examination focuses on studying past and present price action to predict the probability of Golden Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Golden Biotechnology's price. Additionally, you may evaluate how the addition of Golden Biotechnology to your portfolios can decrease your overall portfolio volatility.